<DOC>
	<DOC>NCT00687934</DOC>
	<brief_summary>An open-label dose escalation study of patients with solid tumors treated with STA-9090 (ganetespib)</brief_summary>
	<brief_title>Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Patients must be documented to be refractory or not candidates for current approved therapies. Must have an ECOG status 02. Peripheral neuropathy &lt; or = 2. Must have acceptable organ and marrow function per protocol parameters. No clinically significant ventricular arrythmias or ischemia. Must not be pregnant or breastfeeding. Chemotherapy or radiation within 3 weeks. Previous radiation to &gt;25% of total bone marrow. Previous high dose chemotherapy with autologous or allogeneic hematopoietic stem cell transplantation. Primary brain tumors or active brain metastases. Use of any investigational agents within 4 weeks. Treatment with chronic immunosuppressants. Uncontrolled, intercurrent illness.</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>metastatic cancer</keyword>
	<keyword>solid tumor</keyword>
	<keyword>histologically or cytologically confirmed non-hematological</keyword>
	<keyword>malignancy that is metastatic or unresectable for which no</keyword>
	<keyword>standard therapy exists</keyword>
	<keyword>STA-9090</keyword>
	<keyword>ganetespib</keyword>
</DOC>